IP Library Granted Patent US 8,759,384
Granted Patent B2
US 8,759,384 · App. 12/454,062 · Granted Jun 24, 2014

Oxo-imidazolyl compounds

Inventors: David J. Bearss (Cedar Hills, UT); Hariprasad Vankayalapati (Draper, UT); Yong Xu (Midvale, UT); Charles Erec Stabbins (New York, NY); Vincent A. Fischetti (West Hempstead, NY)
C07D405/06C07D409/06A61K31/4166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,759,384
App. No.
12/454,062
Granted
Jun 24, 2014
Kind
B2
Abstract

Compounds represented by Formula I and II, or pharmaceutically acceptable salts thereof: inhibit bacterial 2-epimerase and are useful anti-infective agents.

Claims (21)

1. A compound represented by Formula I:

or a pharmaceutically acceptable salt thereof, wherein

X is O or S;

Y is S;

Z is O;

A is phenyl;

B is phenyl; or A is phenyl and B is CH 3 ; or A is bromo and B is phenyl;

(R 1 ) n is H;

R 2 in each instance independently is halo, methoxy, or OCF 3 ;

R 3 is H;

R 4 in each instance independently is C 0-4 alkyl, or a single-ringed aryl, hetaryl, or hetcyclyl; and

m is 1 or 2 and mm is 0.

2. The compound according to claim 1 , wherein X is S.

3. The compound according to claim 1 , wherein X is O.

4. The compound according to claim 1 , wherein X is O, A is phenyl, and B is phenyl.

5. The compound according to claim 1 selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 consisting of

or a pharmaceutically acceptable salt thereof.

7. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.

8. A method for treating infections from Staphylococcus aureus, Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus agalactiae , Group C streptococcus , Group G streptococcus, Enterococcus jaecalis, Enterococcus jaecium, Bacillus anthracis, Bacillus cereus, Escherichia coli, Pseudomonas areuginosa, Neisseria meningitides , or Neisseria gonorrhoeae comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 .

Assignments (4)
CHANGE OF NAME Recorded Jan 18, 2013
From: SUPERGEN, INC.
To: ASTEXPHRMACEUTICALS, INC.
Reel/Frame 029871/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2012
From: FISCHETTI, VINCENT A.
To: ROCKEFELLER UNIVERSITY
Reel/Frame 028206/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2012
From: STEBBINS, CHARLES EREC
To: ROCKEFELLER UNIVERSITY
Reel/Frame 028224/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2012
From: BEARSS, DAVID J.; VANKAYALAPATI, HARIPRASAD; XU, YONG
To: ASTEX PHARMACEUTICALS, INC.
Reel/Frame 028206/0148 →
Continuity (2)
Provisional Application 61127494 · May 12, 2008
Related Publication 20090298900A1 · Dec 3, 2009